Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is Ipamorelin? Identity, Receptor Selectivity, and Laboratory Documentation

A research-use identity note on ipamorelin: GHSR selectivity in published models, time-course design, and the lot documents that should accompany laboratory material.

What Is Ipamorelin? Identity, Receptor Selectivity, and Laboratory Documentation

Ipamorelin is a pentapeptide used in endocrine and receptor-signaling research as a growth-hormone secretagogue receptor (GHSR) agonist. The original overview of this page asks three questions: GHSR selectivity and receptor context, endocrine time-course design, and identity and purity testing for the material on the bench.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

Identity and GHSR selectivity

Raun and colleagues described ipamorelin as the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 and reported that it released growth hormone (GH) from primary rat pituitary cells with potency and efficacy similar to GHRP-6, acting through a GHRP-like receptor rather than the GHRH receptor (Raun et al., 1998). In pentobarbital-anaesthetized rats and in conscious swine, the same study reported GH release with potency and efficacy comparable to GHRP-6.

On selectivity, the swine experiments in that paper reported that ipamorelin did not raise ACTH or cortisol to levels significantly different from those seen after GHRH stimulation, including at doses far above the GH-release ED50, whereas GHRP-6 and GHRP-2 increased ACTH and cortisol in the same design (Raun et al., 1998). The authors concluded that ipamorelin was a GHRP-receptor agonist with GH selectivity more like that of GHRH than of earlier GHRP analogues. That is a finding in the models and assays of that paper. It is not a ranking of catalog products and it is not a protocol.

Receptor context still has to be written into the experimental question. A GHSR (ghrelin-receptor) agonist is not a GHRH analogue. For that distinction in a procurement file, see CJC-1295 vs Sermorelin vs Ipamorelin and What Is CJC-1295?.

Endocrine time-course design

Because secretagogue experiments are time-dependent, the original overview flags time-course design as a documentation issue: sampling windows, controls, and the analogue being used should be stated, not inferred from the peptide name. Gobburu and colleagues published a pharmacokinetic-pharmacodynamic model of the GH response to ipamorelin in human volunteers (Gobburu et al., 1999). That paper is a published clinical-research time-course analysis. It is cited here only as an example of how a time-course has been reported; it is not a dosing, administration, or treatment instruction, and it does not describe a current catalog lot.

Identity and purity testing

A useful quality review still separates sequence identity, purity, content, and lot matching. The name “ipamorelin” should appear consistently on the brief, the quotation, the report, and the label, with the same specification and quantity basis. Combination presentations, if offered, are separate line items; a combined SKU is not a substitute for a single-analogue report.

What Is a Peptide COA? and How to Read a Peptide COA cover report review; Third-Party Peptide Testing, Explained and HPLC vs Mass Spectrometry for Peptide Lot Review cover issuer and method questions; lot traceability covers the wider file.

Writing a brief that can be compared

If ipamorelin is a new line in a purchasing file, write the exact name, specification, vial and box counts, destination, and the documents you need to see. A trial quantity, where the catalog allows it, should use the same acceptance criteria as a later shipment. For many B2B catalogs, including Velnacor’s, a standard minimum is one box of ten vials; confirm the unit basis on the quotation.

Do not copy conclusions from a different secretagogue into the ipamorelin row. Raun and colleagues compared several GHRP-receptor ligands in the same swine design; that is still not a reason to treat another catalog GHRP as documented by the ipamorelin report. Neighboring GHRH analogues, including CJC-1295 forms, belong on their own rows even if they ship in the same parcel.

Order-specific questions can go through the inquiry list. How to Evaluate a Peptide Supplier: B2B Checklist keeps documentation questions consistent when more than one supplier is shortlisted.

Catalog notes

Ipamorelin appears in Velnacor’s research-material catalog (internal product record, slug ipamorelin), as do some combination SKUs that include ipamorelin. There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact SKU, specification, and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.

Selected published literature

  1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PubMed 9849822.
  2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. doi:10.1023/A:1018955126402. PubMed 10496658. Cited as published time-course research, not as a use instruction.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0